Skip to main content
About
Contact
Subscribe
e-Edition
Make Home Page
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Twitter
Toggle navigation
Site search
Search
Home
Contact Us
Advertise
Subscription Services
Promote Your Event
Submission Forms
News
Local News
National
World
Archives
Sports
Local Sports
National Sports
Business
Local Business
National Business
Technology
Markets & Stocks
Opinion
Columns
Editorials
Letters To The Editor
Polls
Thumbs
A & E
Local Entertainment
Art Scene
Music Scene
Theatre Scene
Book Reviews
Movie Reviews
TV Listings
Local Events
What To Do
Life
Health
Travel
Oddities
Community Directory
Community Service
Rescue Me
Other
Specials
Spring Home & Garden Show
Home & Realty
Outdoor Guide
Women
Fall Home Improvement
Spring Wellness
Classifieds
Place Ad
Careers
Tenders
Weather
Obituaries
2024 Auction
2024 Readersâ Choice Awards
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Glaukos Corp
(NY:
GKOS
)
98.95
UNCHANGED
Streaming Delayed Price
Updated: 7:00 PM EDT, Apr 22, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Glaukos Corp
< Previous
1
2
3
Next >
Glaukos Announces the Release of its 2023 Sustainability Report
April 16, 2024
From
Glaukos Corporation
Via
Business Wire
Glaukos to Release First Quarter 2024 Financial Results after Market Close on May 1
April 10, 2024
From
Glaukos Corporation
Via
Business Wire
Glaukos Receives Permanent J-code for iDose® TR (travoprost intracameral implant)
April 03, 2024
From
Glaukos Corporation
Via
Business Wire
Glaukos To Present Numerous Scientific Abstracts at the 2024 American Society of Cataract and Refractive Surgery Annual Meeting
April 01, 2024
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Fourth Quarter and Full Year 2023 Financial Results
February 21, 2024
From
Glaukos Corporation
Via
Business Wire
Glaukos to Release Fourth Quarter and Full Year 2023 Financial Results after Market Close on February 21
January 31, 2024
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Net Sales and Reaffirms 2024 Revenue Guidance
January 09, 2024
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Participation in the J.P. Morgan Healthcare Conference
December 20, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces FDA Approval of iDose® TR (travoprost intracameral implant)
December 14, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Participation in Stifel Healthcare Conference
November 07, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Third Quarter 2023 Financial Results
November 01, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Academy of Ophthalmology Annual Meeting
October 31, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos to Release Third Quarter 2023 Financial Results after Market Close on November 1, 2023
October 11, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Participation in Wells Fargo Healthcare Conference
August 23, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Second Quarter 2023 Financial Results
August 02, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos Enters into a Collaboration and Marketing Agreement with Radius XR, Inc.
July 17, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos to Release Second Quarter 2023 Financial Results after Market Close on August 2, 2023
July 12, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos Achieves Pipeline Milestone with Enrollment Completion in Phase 3 Confirmatory Trial for Epioxa (Epi-on)
June 05, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Participation in the William Blair Growth Stock Conference
May 24, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces FDA Acceptance of NDA Submission for iDose TR
May 05, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces First Quarter 2023 Financial Results
May 03, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos Technologies Featured in Numerous Scientific Abstracts at the 2023 American Society of Cataract and Refractive Surgery Annual Meeting
May 01, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces the Release of its 2022 Sustainability Report
April 19, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos to Release First Quarter 2023 Financial Results after Market Close on May 3
April 12, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos Submits New Drug Application to U.S. FDA for iDose TR
February 27, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Fourth Quarter and Full Year 2022 Financial Results
February 22, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Participation in the Citi Healthcare Conference
February 15, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos to Release Fourth Quarter and Full Year 2022 Financial Results after Market Close on February 22
February 01, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Positive Results for iDose TR Exchange Trial, Highlighting Favorable Safety and Tolerability
January 10, 2023
From
Glaukos Corporation
Via
Business Wire
Glaukos Announces Positive Clinical Updates for Several Corneal Health Pipeline Programs
January 10, 2023
From
Glaukos Corporation
Via
Business Wire
< Previous
1
2
3
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.